
Christopher Hahn
Articles
-
1 month ago |
nature.com | Mithun Vinod Shah |Kevin Hung |Anmol Baranwal |Aref Al-Kali |Antoine Saliba |dong chen | +18 more
AbstractThe World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of TP53-mutated (TP53mut) myeloid neoplasm (MN). However, there are substantial differences between the two classifications that may lead to under- or overestimation of the prognostic risk. We retrospectively applied WHO-5 and ICC to 603 MN cases harboring TP53mut (variant allele frequency, VAF ≥ 2%).
-
Mar 4, 2025 |
newsnationnow.com | Jeff Arnold |Christopher Hahn
( NewsNation) - The mayors of four sanctuary cities who will appear before the Republican-led Committee On Oversight and Government Reform on Wednesday could be risking the loss of billions in federal funding for what GOP leaders refer to as a lack of cooperation with federal immigration enforcement efforts. The committee's chairman, U.S. Rep.
-
Apr 24, 2024 |
springerprofessional.de | Christopher Hahn
Dieses essential vermittelt auch in der aktualisierten und überarbeiteten 3. Auflage Gründern innovativer Unternehmen sowie Investoren ein Verständnis für die typischen Regelungen des Beteiligungsvertrages zwischen der Gesellschaft und dem Kapitalgeber. Christopher Hahn erläutert die Funktionsweise des Beteiligungsvertrages und der Gesellschaftervereinbarung sowie der dazugehörigen Nebenvereinbarungen.
-
Jun 8, 2023 |
chemistry-europe.onlinelibrary.wiley.com | John Lin |Thomas F. Jaramillo |Christopher Hahn |Dong Un Lee
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →